eXoZymes Inc. Common Stock

Day range

$3.89 – $4.40

Open

$4.00

Prev close

$4.00

Volume

15.19K

Market cap

$37.22M

Shares out

9.3M

P/E

—

P/S

—

P/B

10.19

P/FCF

—

ROE

-278.9%

ROA

-127.7%

Debt/Equity

0.02

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationOct 9, 2026

  Attached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, dated as of October 6, 2026, that may be provided to investment bankers and other offering participants and current and potential investors in securities of the Company.

• Shareholder meeting noticeSep 18, 2026

  The Company determined to hold its 2026 annual meeting on November 13, 2026, and plans to distribute its proxy statement and proxy to the shareholders on or about September 28, 2026. The record date for the meeting was September 15, 2026.

• Public offeringJul 1, 2026

  The Offering closed on June 30, 2026. The gross proceeds to the Company from the Offering were $639,990, before commissions of $44,799 and other expenses of approximately $30,000. The net proceeds will be used to further develop the opportunities associated with the N-trans-caffeoyltyramine (NCT) business and products developed under the NCT technology of the Company, next in line products, research and development and general corporate purposes, working capital and capital expenditures.

• Underwriting agreementJun 17, 2026

  eXoZymes Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement"), dated as of June 5, 2026, with Public Ventures LLC, doing business as MDB Capital ("MDB"), as the sole underwriter and book runner, pursuant to which the Company issued and sold...an aggregate of 592,270 shares of common stock...and warrants to purchase up to an additional 296,135 shares of Common Stock.

• Underwriting agreementJun 8, 2026

  On June 5, 2026, eXoZymes Inc. (the "Company") entered into (i) an Underwriting Agreement (the "Underwriting Agreement"), dated as of June 5, 2026, with MDB Capital ("MDB"), as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering (the "Offering") an aggregate of 592,270 shares of common stock and 292,135 warrants. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties and termination provisions.

Days to cover

2.0

Short interest

18.47K

Avg volume

9K

As of Sep 30, 2026 · reported to FINRA twice monthly.